Kytopen develops genome engineering platforms that enable cell therapy research and manufacturing.
Kytopen's investors include National Science Foundation, Merck, Alexandria Venture Investments, The Engine, Massachusetts Clean Energy Center.
Kytopen is headquartered in Cambridge, United States.
Kytopen develops genome engineering platforms that enable cell therapy research and manufacturing.
Kytopen is at the Series B stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Kytopen — Funding & Investors." VCBacked, April 7, 2026, https://www.vcbacked.co/company/kytopen. Accessed July 20, 2026.
VCBacked. (2026). Kytopen — Funding & Investors. Retrieved July 20, 2026, from https://www.vcbacked.co/company/kytopen
{{cite web |title=Kytopen — Funding & Investors |url=https://www.vcbacked.co/company/kytopen |website=VCBacked |access-date=July 20, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated